期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 60, 期 5, 页码 2221-2231出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.202003563
关键词
aptamers; artificial bases; biomarker discovery; cancer classification; SELEX
资金
- NSFC [NSFC 21827811, 61527806]
- Science and Technology Project of Hunan Province [2017XK2103]
SELEX technology has shown the ability to evolve artificial ligands with affinity and specificity, and aptamers complement antibodies with unique advantages such as small size, low cost, and facile chemical modification, making them a potential molecular tool for future clinical needs in biomedicine.
The advent of SELEX (systematic evolution of ligands by exponential enrichment) technology has shown the ability to evolve artificial ligands with affinity and specificity able to meet growing clinical demand for probes that can, for example, distinguish between the target leukemia cells and other cancer cells within the matrix of heterogeneity, which characterizes cancer cells. Though antibodies are the conventional and ideal choice as a molecular recognition tool for many applications, aptamers complement the use of antibodies due to many unique advantages, such as small size, low cost, and facile chemical modification. This Minireview will focus on the novel applications of aptamers and SELEX, as well as opportunities to develop molecular tools able to meet future clinical needs in biomedicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据